(Alliance News) - Stock prices in London were lower at midday on Monday, with weakness in technology and financial shares offsetting gains in telecoms stocks, while investors kept a close eye on the latest escalation in the Middle East. Read More
Ixico - London-based medical research company, focused on analysing trial data using neuroscience imaging and biomarkers - Says the discontinuation of two Huntington's disease programmes by existing clients reduces its contracted order book by around GBP1.5 million over the next two financial years. Ixico notes it secured GBP8.0 million of new Huntington's disease programme awards in the first half and says its order book remains 21% above the end of financial 2025. It adds that programme cancellations are a normal feature of drug development and reiterates recently upgraded guidance for financial 2026 and its outlook for 2027. Read More
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Monday. Read More
(Alliance News) - Stock prices in London opened slightly lower on Monday as renewed tensions between the US and Iran lifted oil prices. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Ixico PLC - London-based medical research company, focused on analysing trial data using neuroscience imaging and biomarkers - Reports results for the six months ended March 31. Revenue increases 23% to GBP3.9 million from GBP3.2 million the year before, "driven by new contract wins, contract extensions and an increased volume of analyses". Pretax loss widens to GBP1.6 million from GBP889,000. Sales and marketing expenses increase 23% to GBP1.1 million from GBPGBP862,000, with total operating expenses increasing 19% to GBP3.3 million from GBP2.8 million. Order book totals GBP18.1 million at March 31, up from GBP13.1 million one year prior. Company reaffirms guidance of 15% revenue growth for the full year. Chief Executive Officer Bram Goorden says Ixico "is now in a more stable and resilient position" and "is well placed to deliver on its ambitions and create sustainable value in the years ahead." Read More
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Ixico PLC on Monday hailed an "important" contract win to further research into neurological disorder, Huntington's Disease. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday. Read More
(Alliance News) - European stocks barely budged in early dealings on Monday, with trade lacking impetus as investors look ahead to the end of a data blackout in the US. Read More
(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Ixico PLC - London-based medical research company, focused on analysing trial data using neuroscience imaging and biomarkers - Signs two new commercial contracts worth approximately GBP1.3 million in total. First contract covers around three and a half years, with Ixico providing trial management and imaging analysis for a phase 1 study by "a major pharmaceutical company" on Alzheimer's disease. The second, under which Ixico will facilitate imaging data collection for a phase 1b trial to support surgical planning in Friedrich's ataxia, covers six years and is "with a US-based biotech". "This positive commercial momentum continues IXICO's successful execution of its 'Innovate, Lead, Scale' strategy to drive global expansion and growth," Ixico says. Read More